MiRNA encoded PTEN's Impact on Clinical-Pathological Features and
Prognosis in Osteosarcoma: a Systematic Review and Meta-Analysis
Edward Kurnia Setiawan Limijadi ¹ , Robin Novriansyah ^{2,4} , Danendra Rakha Putra Respati ^{3,4*} ,
Kevin Christian Tjandra ^{3,4} ¶
¹ Department of Clinical Pathology, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
² Department of Orthopaedic Surgery, Faculty of Medicine, Universitas Diopnegoro, Semarang,
Indonesia
³ Departement of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
⁴ Kariadi General Hospital, Semarang, Indonesia
*Corresponding author: Danendra Rakha Putra Respati; Department of Medicine, Faculty of
Medicine, Universitas Diponegoro; Jl. Prof. Sudarto, Tembalang, Kec. Tembalang, Kota
Semarang, Jawa Tengah 50275
Email: rakhapres@gmail.com
[¶] This author contributed equally to this work
Abstract
Background: Osteosarcoma (OSC) is considered one of the most common malignant bone tumours in
adolescents. Due to OSC's poor prognosis, a comprehensive approach to exploring these aspects is
highly needed to improve the survival probability of OSC. In this study, we tried to explore the
significance of miRNA-encoded PTEN for clinical-pathological features and prognostic value in
OSC. Method: We performed this systematic review and meta-analysis using articles and sources
published between 2013 and 2023 from six databases (Scopus, PubMed, ProQuest, Science Direct, Sage
Rubreands Goghrang). Included studies avereclinical crosses etiowal studies not berstudy designs articles

27 not written in English, without full text, and not relevant—were excluded. Then, ROBINS-I is used to evaluate the distance. The results are constructed according to the PICOS criteria in a table. The 28 29 expression of miRNA related to OSC is assessed in the meta-analysis as the main outcome to determine its ability as a diagnostic and prognostic agent for OSC. This systematic review followed the PRISMA 30 31 guidelines. Results: A total of 17 studies were included in the final screening. The meta-analysis showed significantly increased (p < 0.00001) miRNA expression in patients with osteosarcoma 32 33 compared to healthy controlled with pooled md (2.85) (95% CI: 2.69, 3.02; $I^2 = 22\%$, p = 0.20), the high 34 inverse correlation (p < 0.001) between miRNA and PTEN expression was shown as mean effect size (-0.681) (95% CI: -0.787, -0.536; I² = 75%, p < 0.0001), and the prognostic evaluation of overall 35 36 survival was significantly increased in low expression miRNA (p < 0.00001) with pooled OR. Conclusion: Fiveteen miRNAs from 17 studies were found, and together with PTEN expression, 37 38 they may serve as potential prognostic biomarkers for OSC. High-level levels of miRNA expression 39 are correlated with low PTEN expression, leading to a bad prognosis for OSC.

40 Keywords: Osteosarcoma, miRNA-PTEN, Prognosis

41 1. Introduction

Osteosarcoma (OSC) is the most frequent bone malignancy in both children and adults. It is a malignant 42 43 mesenchymal tumour that accounts for 20-40% of all occurrences of bone malignancies. The metaphysis of the long bones in the lower extremities is the most frequent site of OSC, which is most 44 common in people between the ages of five and twenty-five [1]. The inferior extremities, particularly 45 the distal femur, proximal tibia, and proximal humerus, are shown to be the site of 74.5% of cases. In 46 the meantime, factors like as age, gender, tumour location, biomarker levels, onset, and metastatic 47 presence all affect the prognosis of OS. $61\pm15\%$ is the 5-year relative survival rate for all age groups, 48 varying based on disease onset and gender. However, this figure drastically decreases to 20±5% in 49 patients with metastasis. Approximately 10-20% of OSC patients experience metastasis, with the lungs 50 51 being a common site of involvement [2].

52

53 The high fatality rate drives the need for a more comprehensive multidisciplinary approach to the 54 diagnosis and management of OSC. To date, several treatment options for OSC include surgical

excision, radiotherapy, and multi-agent systemic therapy. Several evaluations are required to ascertain which therapy will yield the best response in the patients. Furthermore, invasive biopsy is still required for OSC diagnosis evaluation and confirmation [3,4]. However, due to variations in sample collection, the accuracy of the biopsy-derived diagnosis and prognosis can fluctuate. Therefore, the diagnostic approach is an important aspect to develop to achieve better prognosis, and one method with great potential is identifying biomarkers [5–7].

61

62 Biomarkers themselves can be used as therapeutic, prognostic, and diagnostic agents. MicroRNAs 63 (miRNAs) are a class of endogenous non-coding RNAs with lengths of 19-25 nt. They are involved in 64 differentiation, cell death, and the cell cycle by regulating gene expression through direct inhibition and 65 degradation of mRNA translation [8]. In malignancies, this inhibitory function makes them tumor 66 suppressors and biomarkers for the diagnosis and prognosis of patients. PTEN is one of the major tumor 67 suppressors that has been extensively studied for its effects on cancer development, such as breast 68 cancer, prostate cancer, and lung cancer. PTEN (phosphatase and tensin homolog deleted on 69 chromosome ten) is a candidate tumor suppressor located on chromosome 10q23. PTEN works in the 70 PI3K/AKT regulatory pathway, a lipid kinase family axis with the PIP3 product, which is involved in 71 controlling cell proliferation to prevent cell development into cancer. The increase and decrease in 72 PTEN expression are regulated by a number of proteins in posttranslational, posttranscriptional, and 73 transcriptional mechanisms. One of these proteins is miRNA, which suppresses PTEN expression posttranscriptionally. In this systematic review and meta-analysis, we summarize current knowledge on 74 the correlation between miRNA-PTEN and its impact on the clinicopathological and prognostic aspects 75 76 of OSC, which has not been previously explored within the scope of a wide range of articles.

77 2. Methods

78 <u>Eligibility criteria</u>

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were used for this systematic review [9]. From 2013 to 2023 (last search date September 20th, 2023), we have included original content. The study included original research publications that met the inclusion criteria for autologous clinical cross-sectional. Technical reports, editor's responses, narrative reviews, systematic

83 reviews, meta-analyses, non-comparative studies, in silico studies, in vitro studies, in vivo studies, applied Scientific posters, research proposals, and conference abstracts were all diminished. Articles 84 not written in English, with incomplete content, and not related to the miRNA and PTEN Gene 85 expression in correlation to OSC as well as survival rate were also eliminated. The desired PICO criteria 86 87 of the selected products included i) patients with OSC; ii) miRNA and PTEN expression evaluation 88 towards OSC patients and its survival rate; iii) Comparison, normal cells either obtain from the same 89 patients or other normal patients; and iv) Results, miRNA and PTEN evaluation utilizing RT-qPCR and 90 two years survival rate.

91

92 *Data search and selection*

93 Research for this study were gathered through Scopus, PubMed, ProQuest, Science Direct, Sage Pub, 94 Cochrane database searches. We used the following combined keywords to capture all potentially 95 eligible literature in each databases: "(osteosarcoma) AND (miRNA OR microRNA) AND (PTEN) AND (clinicopathology OR prognosis)". The database was searched from its establishment until 96 September 20th 2023 during 10-year periods prior to this review. The boolean operator was utilized 97 among the Medical Subject Headings (MeSH) keywords determined from national institute of health 98 99 (NIH) national library of medicine browser. The studies were kept using Mendeley Group Reference 100 Manager in the authors' library. Clinical type articles were used as a filter in the Pubmed database, the 101 the research article type was used for the Scopus, PubMed, ProQuest, Science Direct, Sage Pub, Cochrane database filter. All of these processes for article selection were conducted by the two 102 independent authors (DRPR, KCT) who performed the literature searching process. The identified 103 articles from those databases were first filtered according to their titles and abstracts, and then duplicates 104 were eliminated. The same two authors conducted a second round of full-text evaluations for these 105 publications that made it past the first screening round to determine whether they met our 106 inclusion/exclusion criteria. All differences were addressed by engaging in discussions with the other 107 108 author (EKSL, RN), who assessed the suitability of studies for inclusion in the synthesis.

110 *Data extraction*

After the final screening, the pertinent information from studies was retrieved and entered into a Google 111 Spreadsheet. Recorded data in characteristic table consisted of author, year, country, study design, 112 sample size, mean age, miRNA type, miRNA expression with poor prognosis (high or low), and cut-113 114 off. All of the data extraction was done by two independent author (DRPR, KCT). The primary outcome of this study consisting of the survival analysis, miRNA/PTEN correlation, and clinicopathology 115 features (TNM stage, metastasis, and gender). The desired outcome for the survival analysis was 5-year 116 117 Overall Survival (OS), defined as the time from the initiation of therapy until death from any cause. Using hazard ratios (HR), the impact of miRNA expressions on survival was evaluated. If given by the 118 authors, a univariate HR estimate and 95% confidence intervals were taken straight from each study. If 119 120 not, the suggested approach was used to extract the p values of the log-rank tests, 95% confidence 121 intervals, the number of events, and the number of patients at risk in order to estimate the HR [10]. In 122 cases where the number of events and patients at risk was not reported, we use Engauge Digitizer version 4.1 to reconstruct the kaplan-meier curves, then we calculated the HR using the same method 123 as before. In patients with aberrant miRNA, a pooled HR < 1 suggested a better prognosis, whereas a 124 pooled HR > 1 suggested a worse prognosis. 125

126

127 <u>Study Risk of Bias Assessment (Qualitative Synthesis)</u>

Risk-of-bias tool used to assess the bias of included studies was the ROBINS-I from Cochrane 128 129 Collaborations, was used by three independent author (KCT, DRPR, RN). Any disagreements regarding the bias assessment were discussed further and settled between the 3 reviewers. The result is 130 shown in Figure 2. The authors' evaluations were categorized as "low risk," "high risk," or "some 131 concerns" of bias. For analyzing the quality of included studies, we used Newcastle-Ottawa Scale 132 (NOS) from the Ottawa Hospital Research Institute (OHRI), a quality appraisal tool for cohort and 133 crossectional studies which includes 3 domains of assessment: (1) selection of participants; (2) 134 comparability between exposed and non-exposed cohort; and (3) outcome ascertainment [11]. For 135 cross-sectional research, the maximum possible score ranges from 0 to 10, while for cohort studies, it 136

ranges from 0 to 9. Articles with a score of at least 7 were deemed to have "good" quality. To maintain
the validity of the data included in the current investigation, papers that were judged to have a high risk
of bias will be eliminated from the systematic review.

140

141 <u>Statistical Analysis</u>

The results were displayed in the characteristic table as, mean difference (MD) with standard deviation 142 (SD) for miRNA expression with poor prognosis, HR with a 95% confidence interval (CI) for OS, and 143 144 correlation coefficient (r) with a 95%CI for miRNA/PTEN expression. Gender, TNM stage, and 145 metastatic status were presented as odd ratios (OR) with 95% CI. For pooled analysis, we converted the 146 data expressed as median and interquartile range (IQR) or as median, minimum, and maximum into 147 mean and standard deviations (SD) using a combination formula from Luo D et al. and Wan X et al [12,13]. The I-squared (I2) statistic was employed in this review to evaluate the heterogeneity amongst 148 149 studies, with I2 values greater than 50% classified as significant heterogeneity. When the included 150 studies were deemed homogeneous (little variability in study results or variation owing to random error), as shown by an $P \ge 0.10$ or $I2 \le 50\%$, meta-analysis was performed using a fixed-effect model 151 (FEM). Otherwise, we used a random-effect model (REM) if P < 0.10 or $I^2 > 50\%$. The pooled mean 152 153 difference estimate was presented in a forest plot. When there were more than 10 studies on each outcome of interest, a publication bias analysis was conducted using the funnel plot and Egger's test; if 154 an asymmetry in the funnel plot was discovered, we planned to review the characteristics to determine 155 whether the observed asymmetry could be attributed to publication bias or alternative factors such as 156 methodological heterogeneity among the studies. All of the analyses were carried out using 157 Comprehensive Meta-Analysis software, which can be accessed at https://meta-analysis.com/. 158

159

160 **3. Result**

161 <u>Study Selection</u>

A total of 12,939 studies were found in the database (5622 from Scopus, 31 from Pubmed, 5311 from
Proquest, 1720 from Science Direct, 116 from Sage Pub, and 156 from Cochrane). Then, 4842 studies

164 were imported to the Mendeley Group Reference Manager in the authors' library after the aforementioned criteria were added, and this was done before the selection procedure. The number of 165 4312 studies was eliminated from this process due to irrelevant topics. Eventually, 561 studies were 166 screened manually by the authors. Out of all, 530 studies, they did not provide sufficient data to answer 167 168 the research question, and because their study designs did not meet the criteria for inclusion (clinical cross-sectional), two studies were removed due to duplication, and three were removed due to 169 irretrievable full text. The retrieval of the complete text for the remaining twenty-six studies was then 170 tested. After the full text reading was done, only seventeen articles were considered eligible to be 171 obtained as a result. The flow chart for the PRISMA diagram illustrating our research selection 172 procedure is shown in Figure 1. Using the Cochrane ROBINS-I tool, the seventeen included studies 173 were evaluated for eligibility. All seventeen of the listed studies from this process passed the evaluation 174 175 bias check. The PRISMA flow chart contained records of the research selection procedures.

176

177 **Figure 1.** PRISMA 2020 flow diagram.

178

179 <u>Study Characteristics</u>

The seventeen studies that made up this systematic review comprised a total of 760 participants. These
each four studies were conducted in different countries. Studies were carried out in Japan, South Korea,
France, China, USA, Iran, Singapore, and Spain. The complete study characteristics, including the
PICO of each study, are stated in Table 1.

185 Table 1. Study Characteristic

186				G 1	Samp	le size			
187	No	Author	miR type	type	miRNA high	miRNA low	Cut off	expression	method
188	1	Zhao D., et.al.;2017	miRNA-19a	Tissue	25	25	NR	upregulated	RTq-PCR
189	2	Chen J., et.al.;2015	miRNA-130a	Tissue	86	86	median	upregulated	RTq-PCR
190	3	Yuan H., et.al.;2015	miRNA-1908	Tissue	46	9	NR	upregulated	RTq-PCR
191	4	Hu X., et.al.;2018	miRNA-21	Tissue	46	20	NR	upregulated	RTq-PCR
192	5	Liu Q., et.al.;2018	miRNA-29	Tissue	60	60	median	upregulated	RTq-PCR
193	6	Liu J., et.al.;2015	miRNA-214	Tissue	22	22	NR	upregulated	RTq-PCR
194	7	Gao Y., et.al.;2014	miRNA-17	Tissue	28	28	NR	upregulated	RTq-PCR
195	8	Zhuang M., et.al.;2018	miRNA-524	Tissue	20	20	NR	upregulated	RTq-PCR
196	9	Sun C.,et.al.;2022	miRNA- 181a-5p	Tissue	N/A	N/A	NR	upregulated	RTq-PCR
107	10	Zhang H.,et.al.;2016	miRNA-148a	Tissue	92	92	median	upregulated	RTq-PCR
197	11	Zhu J.,et.al.;2015	miRNA-221	Tissue	16	12	NR	upregulated	RTq-PCR
198	12	Yu W.,et.al.;2020	miRNA-744	Tissue	25	25	NR	upregulated	RTq-PCR
199	13	Fu Y.,et.al.;2020	miRNA- 208a-3p	Tissue	10	10	NR	upregulated	RTq-PCR
200	14	Xiao J.,et.al.;2017	miRNA-92a	Tissue	68	68	median	upregulated	RTq-PCR
201	15	Yu L.,et.al.;2017	miRNA-214	Tissue	15	15	NR	upregulated	RTq-PCR
202	16	Tian Z.,et.al.;2014	miRNA-128	Tissue	100	100	median	upregulated	RTq-PCR
203	17	Zhao H.,	miRNA-21	Tissue	NR NP	NR NP	median	upregulated	RTq-PCR
204		et.al;2019	1111 NINA- 221		INK	INK			

205 <u>Risk of Bias in Studies</u>

Each cohort and cross-sectional study underwent a thorough assessment of its quality using the ROBINS-I risk-of-bias method. In nine of the investigations, there were four studies identified as a study with some concern of bias due to unclear randomization process between the allocation of intervention and control groups. An overview of the bias risk assessment is shown in **Figure 2**.

210

211 Figure 2. Risk of Bias Assessment

213

214 <u>Clinicopathologies</u>

A meta-analysis of five studies was used to evaluate the gender clinicopathologic relationship between 215 OSC overexpression and miRNA encoding PTEN. A non-significant effect (P = 0.28) with a pooled 216 217 odds ratio (OR) of (1.24) (95% CI: 0.84, 1.83) is seen in Figure 3 forest plot. This outcome suggests 218 that events do not differ for males and females. Additionally, the forest plot demonstrated heterogeneity for the gender odds ratio clinicopathology ($I^2 = 0\%$; P = 0.53). Figure 4 displays an analysis of the 219 metastatic clinicopathologic associated with miRNA encoding PTEN for OSC from three journals. A 220 significant effect (P < 0.00001) was seen in the forest plot, with a pooled OR of 0.24 (95% CI: 0.13, 221 0.43). The combined OR showed that an increase in the events leading to OSC metastasis was caused 222 by over-expression of the miRNA encoding PTEN. The results showed heterogeneity ($I^2 = 12\%$; P = 223 224 0.32). The assessment of OSC development entailed a review of its TNM staging concerning miRNA 225 encoding PTEN, as shown in Figure 5. A significant effect (P = 0.02) can be seen in the forest plot, 226 where the pooled odds ratio (OR) was 0.59 (95% CI: 0.38, 0.93). The cumulative OR indicated that an 227 unfavourable prognosis for OSC was linked to over-expression of miRNA encoding PTEN. Heterogeneity was notably found ($I^2 = 11\%$; P = 0.35). 228

229

230 Figure 3. Forest plot of gender-related to miRNA overexpression

231

Figure 4. Forest plot of metastasis-related to miRNA overexpression

233

Figure 5. Forest plot of TNM staging related to miRNA encoding PTEN overexpression

235

236 <u>Prognostic survival analysis</u>

237 The correlation between OS rate and miRNA overexpression was thoroughly examined in this study.

- 238 The assessment, depicted in Figure 6 through meta-analysis, revealed a substantial effect (P < 0.00001),
- with a pooled Hazard Ratio (HR) of -12.38 (95% CI: -13.75, -11.01). The aggregated HR underscored

- that OSC patients exhibiting miRNA encoding PTEN overexpression face a mortality risk more than
- twice as high. Noteworthy heterogeneity was observed ($I^2 = 20\%$; P = 0.27).
- 242
- **Figure 6.** Forest plot of overall survival related to miRNA encoding PTEN overexpression
- 244
- 245 *miRNA and PTEN correlation for osteosarcoma expression*
- A meta-analysis comparing the population with OSC to the healthy population was conducted as part 246 of the inquiry into miRNA overexpression. A significant effect (P < 0.00001) was seen in the forest 247 plot, as shown in Figure 7, with a pooled mean difference (MD) of 2.83 (95% CI: 2.65, 3.02). When 248 249 comparing the expression of miRNA in patients with OSC to that in healthy individuals, the combined MD showed a substantial increase in expression. Heterogeneity was found, notably ($I^2 = 27\%$; P = 0.16). 250 Meanwhile, this meta-analysis examined PTEN expression and its relationship to miRNA expression. 251 This result was shown in Figure 8. A significant effect (P < 0.00001) was seen in the forest, with a 252 pooled mean difference (MD) of -1.51 (95% CI: -1.68, -1.34). PTEN expression was lower in patients 253 with miRNA overexpression, according to the pooled MD. Heterogeneity was found ($I^2 = 77\%$; P < 254 0.00001). 255
- 256
- 257 Figure 7. Forrest plot of high/low miRNA expression
- 258
- **Figure 8.** Forrest plot of miRNA and PTEN expression correlation
- 260

261 <u>Reporting biases</u>

- Egger's test and Begg's funnel plot were used to assess the meta-analysis's publication bias. The funnel
- plot among the 13 research did not clearly demonstrate any signs of asymmetry, as **Figure 9** illustrates.
- Furthermore, Egger's test in the meta-analysis indicated no evidence of publication bias (P>0.05).
- 265
- 266 Figure 9. Funnel plot of high/low miRNA expression
- 267

268 4. Discussion

The identification of Phosphatase and tensin homolog deleted on chromosome ten (PTEN) dates back 269 to 1997. It marked the inaugural recognition of a tumor suppressor gene possessing tyrosine 270 phosphatase activity. The nomenclature "phosphatase and tensin homolog deleted on chromosome ten" 271 272 was derived from its location at 10q23 [14]. Crucial to the principal regulatory pathway of cell growth 273 is phosphatidylinositol 3.4.5-trisphosphate (PIP3), capable of stimulating cell growth and initiating 274 tissue cell apoptosis [15]. PTEN intervenes by dephosphorylating one of the three phospho-groups of 275 PIP3, modulating the cell growth pathway and prompting cellular self-destruction, thereby instigating 276 abnormal cell death[16]. Furthermore, PTEN's tumor suppressor role extends to cell cycle regulation, 277 where it fosters p27Kip1 binding to the CyclinE/cyclin-dependent kinase 2 (CDK2) complex, inhibiting 278 CDK2 kinase activity. This inhibition prevents cells from entering the S phase and correlates with the 279 down-regulation of RB protein phosphorylation levels [17].

280

PTEN down-regulation has been documented in various malignant tissues such as glioma, endometrial cancer, lung cancer, and prostate cancer [8,18,19]. Previous investigations into the impact of PTEN expression on OSC patient prognosis yielded conflicting results. For instance, Sun et al. [16] posited that positive PTEN expression is unrelated to gender, age, tumor size, and metastasis, while Han et al. and Xie et al [20–22]. reported an association between PTEN expression and OSC metastasis. In this comprehensive report, a meta-analysis encompassing all available studies on PTEN expression and OSC patients was conducted to elucidate its relationship with the prognosis of OSC.

288

This study demonstrates that PTEN is a direct target of multiple miRNAs, including miRNA-19a, miRNA-130a, miRNA-1908, miRNA-21, miRNA-29, miRNA-17, miRNA-524, miRNA-181a-5p, miRNA-148a, miRNA-221, miRNA-744, miRNA-208a-3p, miRNA-92a, miRNA-214, and miRNA-128, which are overexpressed in OSC tissues compared to normal tissues. PTEN shows a negative correlation with miRNA expression in OSC tissue. Studies by Gao Y. (2014) demonstrated PTEN as a target of miRNA-17, suppressing the WT 3'-UTR in HEK293 cells [23]. Yuan H (2015) reported that miR-1908 overexpression reduces PTEN expression, confirmed through luciferase activity comparison

in OSC cells transfected with miRNA-1908 [24]. Xiao J. (2017) reported increased miR-92a expression
reduces PTEN levels, leading to increased expression of p-AKT(Ser473), mTOR, p-p27(Thr157), and
p-MDM2(Ser166) in MG-63 cells, indicating miR-92a regulates the PTEN/AKT pathway in OSC cells
[25].

300

Previous studies have detailed the post-transcriptional regulation of oncogenes and tumor suppressors 301 by microRNAs (miRNAs), involving epigenetic mechanisms such as DNA methylation, chromatin 302 303 modification, and non-coding RNAs (ncRNAs), including miRNAs and long non-coding RNAs (IncRNAs). MiRNAs targeting PTEN primarily focus on the slender region of the 3' untranslated region 304 305 (3'UTR), leading to the downregulation of PTEN expression [8,19]. Consequently, the overexpression of miRNAs suppresses PTEN function in the PI3K/Akt pathway, promoting OSC growth [26,27]. In 306 307 tumor cells, PTEN acts as an anti-proliferative agent by inhibiting cyclin D1 transcription through AKT 308 inactivation and increasing lipid phosphatase activity in the cytoplasm, resulting in elevated p27 309 expression. PTEN also mediates apoptosis through the activation of caspase-3 and TP53 [28]. 310 Furthermore, PTEN regulates the Epithelial Mesenchymal Transition (EMT), an early stage in the 311 metastasis cascade [29,30]. Thus, PTEN indirectly influences the prognosis of OSC and other tumors, 312 such as breast, kidney, and lung cancers [31–33].

313

314 We further analyzed the correlation between the expression of these miRNAs and the prognosis and clinicopathological features of OSC. A comprehensive systematic review and meta-analysis clarified 315 316 the prognostic value of miRNAs and PTEN in OSC. An increase in miRNAs targeting PTEN in OSC tissues closely correlates with worse OS Xiao J. (2017) reported that OS tissues with overexpression of 317 miRNA-92a have worse overall and event-free survival (EFS) [25]. Detailed confirmation of the role 318 of miRNAs in OSC prognosis was provided by Zhao H. (2019), comparing miRNA-128-high/PTEN-319 low, miRNA-128-low/PTEN-high, and miR-128-low/PTEN-low groups, showing that upregulation of 320 miRNA-128 and downregulation of PTEN constitute the group with the worst prognosis and 321 clinicopathological features [34]. Zhang H. (2016) explained their findings regarding the correlation 322

323 between overexpression of miRNA-148a in OSC tissues and worse OS and clinicopathological features

324 [35].

325

It is essential to note that OSC prognosis can be influenced by various risk factors beyond miRNA 326 327 expression, with patient clinicopathological features also playing a role. Therefore, we evaluated the 328 relationship between miRNA expression and OSC clinicopathological features. The relevance of each 329 clinicopathological feature and the overexpression of miRNAs to OSC prognosis was explained in a 330 study by Zhao H. (2019) [34]. MiRNA-21, miRNA-221, metastasis, and tumor staging were identified as major independent risk factors impacting OSC prognosis compared to other parameters. It was also 331 indicated that the overexpression of miRNA-21 and miRNA-221 has a more significant impact on worse 332 333 prognosis than metastasis and tumor staging. To further confirm these findings, we investigated the 334 correlation of miRNAs with gender, metastasis, and OSC staging.

335

We found that positive miRNA expression significantly associated with female gender, metastasis, TNM staging, and poor prognosis. Chen J. (2015) suggested that overexpression of miRNA-130a promotes OSC metastasis and EMT through PTEN inhibition, confirmed by transwell assay results showing increased migration and invasion in HOS58 cells [36]. Hu X. (2018) and Zhu J. (2015) indicated that positive expression of miRNA-21 and miRNA-221 increases proliferation, invasion, and migration through PTEN downregulation, subsequently promoting metastasis [37,38].

342

The study exhibits several strengths, including a comprehensive approach through systematic review 343 and meta-analysis, involving 17 studies published between 2013 and 2023 from diverse databases. 344 Methodological rigor is maintained with the use of the ROBINS-I tool for risk assessment, and 345 adherence to PRISMA guidelines ensures transparency. Clinically relevant outcomes are explored, 346 shedding light on the significance of miRNAs encoded PTEN in OSC. However, limitations include a 347 restriction to clinical cross-sectional studies, potentially limiting the diversity of evidence. Exclusion of 348 349 non-English articles introduces language bias, and the temporal limitation to 2013-2023 might overlook 350 newer developments. Heterogeneity in meta-analysis and the focus on a limited set of outcome

measures may impact the generalizability and comprehensiveness of the findings. Overall, the study suggests 15 miRNAs, in conjunction with PTEN expression, as potential prognostic biomarkers for OSC, though the findings should be interpreted considering these limitations.

354

However, this study has several unavoidable limitations. First, the analysis is based on a set of publications. Second, some Hazard Ratios (HR) and 95% Confidence Intervals (CI) were obtained through survival curve extraction, potentially reducing study accuracy. Third, the majority of studies were conducted in the Asian region, which may affect the generalizability of the results. Fourth, some included studies had small sample sizes, potentially increasing sample bias and randomization errors.

360

361 5. Conclusion

Using a meta-analysis technique, we examined the clinicalpathology characteristics and prognostic usefulness of miRNA-encoded PTEN in patients with OSC in this study. In conclusion, the overexpression of miRNAs encoded PTEN contributes to the unfavourable clinicopathological features and the prognosis of OSC. These factors are primarily associated with female gender, metastasis, and advanced TNM staging. Furthermore, miRNA expression has a greater impact on the decreased OS in OSC.

368

369 STATEMENTS AND DECLARATIONS

370 **Registration**

On August 8, 2023, this systematic review and meta-analysis was registered to the Open Science
Framework (OSF). The registration was identified as MiRNA encoded PTEN's Impact on ClinicalPathological Features and Prognosis in Osteosarcoma: a Systematic Review and Meta-Analysis.
https://doi.org/10.17605/OSF.IO/647WF.

376 Availability of data and materials:

377 <u>Underlying data</u>

- 378 All data underlying the results are available as part of the article and no additional source data are
- 379 required.
- 380 <u>Reporting guidelines</u>
- 381 Data are available under the terms of the <u>Creative Commons Attribution 4.0 International license</u>
- 382 (CC-BY 4.0).
- 383 Competing Interest: All authors declare that they have no competing interests
- 384 Funding: None
- 385 Acknowledgment: None
- 386 Ethical Approval: Not applicable
- 387 Patient's Consent for Publication: Not applicable
- 388

389 **REFERENCES**

- Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global
 assessment. Cancer Causes & Control. 2015 Aug 9;26(8):1127–39.
- Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to
 2004. Cancer. 2009 Apr 1;115(7):1531–43.
- 394 3. Bacci G, Longhi A, Ferrari S, Briccoli A, Donati D, De Paolis M, et al. Prognostic
- 395 Significance of Serum Lactate Dehydrogenase in Osteosarcoma of the Extremity: Experience
- at Rizzoli on 1421 Patients Treated over the Last 30 Years. Tumori Journal. 2004 Sep
- 397 17;90(5):478–84.
- Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment Where do we stand? A
 state of the art review. Cancer Treat Rev. 2014 May;40(4):523–32.
- 400 5. Wadhwa N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors.

401	Indian J	Orthop.	2014 1	May;48(3	3):247–54.
-----	----------	---------	--------	----------	------------

- 402 6. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary
- 403 Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant
- 404 Cooperative Osteosarcoma Study Group Protocols. Journal of Clinical Oncology. 2003 May
- 405 15;21(10):2011–8.
- 406 7. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic
- 407 Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702
- 408 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. Journal of
- 409 Clinical Oncology. 2002 Feb 1;20(3):776–90.
- 410 8. Kobayashi E, Hornicek FJ, Duan Z. MicroRNA Involvement in Osteosarcoma. Sarcoma.
 411 2012;2012:359739.
- 412 9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T C, Mulrow CD et al. The
- 413 PRISMA 2020 statement: an updated guideline for reporting systematic

414 reviews*BMJ* 2021; 372 :n71 doi:10.1136/bmj.n71

- 415 10. Guyot, P., Ades, A., Ouwens, M.J. *et al.* Enhanced secondary analysis of survival data:
- 416 reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res*

417 *Methodol* **12**, 9 (2012). https://doi.org/10.1186/1471-2288-12-9

- 418 11. GA WellsBS, O'Connell D, Peterson J, et al. The Newcastle- Ottawa scale (NOS) for
- 419 assessing the quality of nonrandomised studies in meta- analyses. 2013.
- Wan, X., Wang, W., Liu, J. *et al.* Estimating the sample mean and standard deviation from the
 sample size, median, range and/or interguartile range. *BMC Med Res Methodol* 14, 135 (2014).
- Sumpre Size, median, range and or merequarite range. Dire med res methodologi 1, 150 (2011
- 422 https://doi.org/10.1186/1471-2288-14-135. doi.org/10.1186/1471-2288-14-135
- 423 13. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size,
- 424 median, mid-range, and/or mid-quartile range. *Statistical Methods in Medical Research*.
- 425 2018;27(6):1785-1805. doi:<u>10.1177/0962280216669183</u>
- 426 14. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and
- 427 prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1
- 428 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 Mar;109:36–50.

429	15.	Zhao X, Wu Q, Gong X, Liu J, Ma Y. Osteosarcoma: a review of current and future
430		therapeutic approaches. Biomed Eng Online. 2021 Mar 2;20(1):24.
431	16.	Zamborsky R, Kokavec M, Harsanyi S, Danisovic L. Identification of Prognostic and
432		Predictive Osteosarcoma Biomarkers. Med Sci (Basel). 2019 Feb 11;7(2).
433	17.	Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr. The
434		role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell
435		cycle arrest and tumor growth inhibition. J Biol Chem. 2003 Jun 27;278(26):23441-50. doi:
436		10.1074/jbc.M300848200.
437	18.	Dong Z, Liao Z, He Y, Wu C, Meng Z, Qin B, et al. Advances in the Biological Functions and
438		Mechanisms of miRNAs in the Development of Osteosarcoma. Technol Cancer Res Treat.
439		2022;21:15330338221117386.
440	19.	Llobat L, Gourbault O. Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.
441		Biomedicines. 2021 Apr 23;9(5).
442	20.	Sun C, Chen C, Chen Z, Guo J, Yu ZH, Qian W, et al. MicroRNA-181a-5p Promotes
443		Osteosarcoma Progression via PTEN/AKT Pathway. Analytical Cellular Pathology. 2022 Mar
444		8;2022:1–13.
445	21.	Xie L., Liao Y., Shen L., Hu F., Yu S., Zhou Y., Zhang Y., Yang Y., Li D., Ren M., et al.
446		Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on
447		RNA-seq. Oncotarget. 2017;8:42525-42536. doi: 10.18632/oncotarget.17208.
448	22.	Han G, Wang Y, Bi W, Jia J, Wang W. MicroRNA-124 functions as a tumor suppressor and
449		indicates prognosis in human osteosarcoma. Exp Ther Med. 2015;9:679-684.
450	23.	Gao Y, Luo L hui, Li S, Yang C. miR-17 inhibitor suppressed osteosarcoma tumor growth and
451		metastasis via increasing PTEN expression. Biochem Biophys Res Commun. 2014
452		Feb;444(2):230–4.
453	24.	Yuan H, Gao Y. MicroRNA-1908 is upregulated in human osteosarcoma and regulates cell
454		proliferation and migration by repressing PTEN expression. Oncol Rep. 2015
455		Nov;34(5):2706–14.
456	25.	Xiao J, Yu W, Hu K, Li M, Chen J, Li Z. miR-92a promotes tumor growth of osteosarcoma by

457		targeting PTEN/AKT signaling pathway. Oncol Rep. 2017 Mar;37(4):2513-21.
458	26.	Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes
459		Cancer. 2010 Dec;1(12):1170-7.
460	27.	Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene.
461		2008 Sep 18;27(41):5497–510.
462	28.	He L. Posttranscriptional Regulation of PTEN Dosage by Noncoding RNAs. Sci Signal. 2010
463		Nov 2;3(146).
464	29.	Qi Y, Liu J, Chao J, Scheuerman MP, Rahimi SA, Lee LY, et al. PTEN suppresses epithelial-
465		mesenchymal transition and cancer stem cell activity by downregulating Abi1. Sci Rep. 2020
466		Jul 29;10(1):12685.
467	30.	Fedorova O, Parfenyev S, Daks A, Shuvalov O, Barlev NA. The Role of PTEN in Epithelial-
468		Mesenchymal Transition. Cancers (Basel). 2022 Aug 3;14(15):3786.
469	31.	Baig RM, Mahjabeen I, Sabir M, Masood N, Hafeez S, Malik FA, et al. Genetic changes in the
470		PTEN gene and their association with breast cancer in Pakistan. Asian Pac J Cancer Prev.
471		2011;12(10):2773-8.
472	32.	Liu L, Huang L, He J, Cai S, Weng Y, Huang S, et al. PTEN inhibits non-small cell lung
473		cancer cell growth by promoting G0/G1 arrest and cell apoptosis. Oncol Lett. 2018 Nov 16
474	33.	Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, et al. Molecular Signatures
475		of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after
476		Nephrectomy. Cancer Epidemiology, Biomarkers & Prevention. 2009 Mar 1;18(3):894–900.
477	34.	Zhao H, Yan P, Wang J, Zhang Y, Zhang M, Wang Z, et al. Clinical significance of tumor
478		miR-21, miR-221, miR-143, and miR-106a as biomarkers in patients with osteosarcoma. Int J
479		Biol Markers. 2019 Jun 14;34(2):184–93.
480	35.	Zhang H, Wang Y, Xu T, Li C, Wu J, He Q, et al. Increased expression of microRNA-148a in
481		osteosarcoma promotes cancer cell growth by targeting PTEN. Oncol Lett. 2016
482		Nov;12(5):3208–14.
483	36.	Chen J, Yan D, Wu W, Zhu J, Ye W, Shu Q. MicroRNA-130a promotes the metastasis and
484		epithelial-mesenchymal transition of osteosarcoma by targeting PTEN. Oncol Rep. 2016

485		Jun;35(6):3285–92.
486	37.	Hu X, Li L, Lu Y, Yu X, Chen H, Yin Q, et al. miRNA-21 inhibition inhibits osteosarcoma
487		cell proliferation by targeting PTEN and regulating the TGF- β 1 signaling pathway. Oncol Lett.
488		2018 Jul 19
489	38.	Zhu J, Liu F, Wu Q, Liu X. miR-221 increases osteosarcoma cell proliferation, invasion and
490		migration partly through the downregulation of PTEN. Int J Mol Med. 2015 Nov;36(5):1377-
491		83.
492		

Study	Bias due to confounding	Bias in selection of participants into the study	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported result	Overall Bias
Zhao D., et.al.;2017	Low	Low	Low	Low	Low	Low	Low	Low
Chen J., et.al.;2015	Low	Low	Low	Low	Low	Low	Low	Low
Yuan H., et.al.;2015	Low	Low	Low	Low	Low	Low	Low	Low
Hu X., et.al.;2018	Low	Low	Low	Low	Low	Low	Low	Low
ilu Q., et.al.;2018	Low	Low	Low	Low	Low	Low	Low	Low
lu J., et.al.;2015	Low	Low	Low	Low	Low	Low	Low	Low
iao Y., et.al.;2014	Low	Low	Low	Low	Low	Low	Low	Low
huang M., et.al.;2018	Moderate	Low	Low	Moderate	Low	Low	Low	Moderate
un C.,et.al.;2022	Moderate	Low	Low	Moderate	Low	Low	Low	Moderate
hang H.,et.al.;2016	Low	Low	Low	Low	Low	Low	Low	Low
hu J.,et.al.;2015	Low	Low	Low	Low	Low	Low	Low	Low
w W.,et.al.;2020	Low	Low	Low	Low	Low	Low	Low	Low
u Y.,et.al.;2020	Low	Moderate	Low	Moderate	Low	Low	Low	Moderate
liao J.,et.al.;2017	Low	Low	Low	Low	Low	Low	Low	Low
/u L.et.al.;2017	Low	Low	Low	Low	Low	Low	Low	Low
lan Z.,et.al.;2014	Low	Low	Low	Low	Low	Low	Low	Low
(hao, et.al.;2019	Low	Moderate	Low	Low	Low	Low	Low	Moderate

Figure 2. Risk of Bias Assessment

2.3 Gender

Study or Subgroup	Weight	Odds Ratio M-H, Fixed, 95% CI	Odds Ratio M-H, Fixed, 95% CI
Xiao miR-92a 2017	23.0%	0.61 [0.23, 1.62]	
Zhao miR-221 2019	21.3%	1.09 [0.45, 2.62]	
Chen miRNA-130a 2015	20.5%	1.30 [0.55, 3.05]	
Tian miR-128 2014	18.7%	1.63 [0.70, 3.80]	+
Zhao miR-21 2019	16.6%	1.79 [0.75, 4.30]	+
Total (95% CI)	100.0%	1.24 [0.84, 1.83]	•
Heterogeneity: Chi ² = 3.18,	df = 4 (P =)	0.53); l ² = 0%	
Test for overall effect: Z = 1	.07 (P = 0.2	(8)	0.01 0.1 1 10 100 Male Female

medRxiv preprint doi: https://doi.org/10.1101/2024.05.16.24307477; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 3. Forest plot of gender-related to miRNA overexp

2.1 Metastasis

Study or Subgroup	Weight	Odds Ratio M-H, Fixed, 95% Cl	M	Odds Rat H, Fixed, 95	io 3% CI	
Tian miR-128 2014	50.5%	0.19 [0.08, 0.47]		-		
Chen miRNA-130a 2015	41.4%	0.20 [0.08, 0.53]	-			
Xiao miR-92a 2017	8.1%	0.73 [0.15, 3.52]	-	-	-	
Total (95% CI)	100.0%	0.24 [0.13, 0.43]		•		
Heterogeneity: Chi ² = 2.26	, df = 2 (P	= 0.32); l ² = 12%				
Test for overall effect: Z =	4.68 (P < 0	0.00001)	0.01 0.1	1	10	100
				OS Cor	1	

medRxiv preprint doi: https://doi.org/10.1101/2024.05.16.24307477; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 4. Forest plot of metastasis-related to miRNA over

2.2 TNM Stage

Otudu or Outure	Weight	Odds Ratio	Odds	Ratio
studyor subgroup	weight	m-n, Fixed, 99% C	1 NER, PD0	EG, 95% CI
Xiao miR-92a 2017	11.3%	0.14 [0.02, 1.25		+
Chen miRNA-130a 2015	30.5%	0.31 [0.12, 0.81		
Zhao miR-21 2019	8.2%	0.62 [0.12, 3.08		<u> </u>
Liu miRNA-29 2018	17.5%	0.67 [0.24, 1.85		+
Tian miR-128 2014	14.0%	0.78 [0.26, 2.34	·	-
Yuan miRNA-1908 2015	12.8%	0.82 [0.26, 2.55	·	<u> </u>
Zhao miR-221 2019	5.8%	1.80 [0.48, 6.79	i —	-
Total (95% CI)	100.0%	0.59 [0.38, 0.93	ı 🔶	
Heterogeneity: Chi ² = 6.73,	df = 6 (P = 0	0.35); l² = 11%		
Test for overall effect: Z = 2	2.28 (P = 0.0	(2)	0.01 0.1	1 10 100
			Favours [experimental]	Favours [control]

medRxiv preprint doi: https://doi.org/10.1101/2024.05.16.24307477; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 5. Forest plot of TNM staging related to miRNA en

2.4 Overall survival

Study or Subgroup	Weight	Hazard Ratio IV, Fixed, 95% CI	Hazard IV, Fixed	Ratio ,95% CI
Tian miR-128 2014	2.2%	7.88 [1.71, 36.23]		
Zhao miR-21 2019	4.6%	4.00 [1.37, 11.63]		
Zhao miR-221 2019	4.5%	3.65 [1.24, 10.79]		-
Xiao miR-92a 2017	14.2%	3.54 [1.93, 6.50]		+
Yuan miRNA-1908 2015	4.2%	3.21 [1.05, 9.81]	ł	-
Chen miRNA-130a 2015	14.2%	2.40 [1.31, 4.41]		-
Liu miR-214 2015	23.6%	1.84 [1.15, 2.95]	·	*
Zhang miR-148a 2015	20.1%	1.68 [1.01, 2.80]	ŀ	
Hu miR-21 2018	12.5%	1.63 [0.85, 3.11]	t	•
Total (95% CI)	100.0%	2.29 [1.82, 2.88]		•
Heterogeneity: Chi2 = 9.94,	df = 8 (P =	0.27); l ² = 20%	0.001 0.1 1	10 1000
Test for overall effect: Z = 7	7.10 (P < 0.	00001)	Low	High

medRxiv preprint doi: https://doi.org/10.1101/2024.05.16.24307477; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 6. Forest plot of overall survival related to miRNA

1.1 miRNA expression

	5	td. Mean Difference	Std. Mean Difference
Study or Subgroup	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Fu miRNA-208a-3p 2020	1.2%	3.61 [2.09, 5.14]	
Yu miRNA-214 2017	2.0%	3.38 [2.22, 4.55]	
Zhuang miRNA-524 2018	2.7%	3.36 [2.36, 4.35]	
Yu miRNA-744 2020	3.4%	3.32 [2.44, 4.19]	
Liu miRNA-29 2018	7.1%	3.28 [2.72, 3.83]	
Chen miRNA-130a 2015	9.3%	3.23 [2.77, 3.69]	-
Yuan miRNA-1908 2015	3.0%	3.03 [2.11, 3.96]	
Sun miR-181a-5p 2022	10.5%	2.99 [2.57, 3.40]	
Yu miR-130b 2015	8.4%	2.98 [2.49, 3.47]	-
Gao miR-17 2014	4.3%	2.87 [2.11, 3.63]	
Liu miR-214 2015	3.6%	2.72 [1.88, 3.56]	
Zhao miR-19a 2017	4.2%	2.62 [1.85, 3.40]	
Tian miR-128 2014	11.7%	2.59 [2.21, 2.97]	-
Zhang miR-148a 2015	11.2%	2.58 [2.18, 2.97]	-
Zhu miR-221 2015	2.5%	2.52 [1.49, 3.55]	
Hu miR-21 2018	5.2%	2.45 [1.77, 3.13]	
Xiao miR-92a 2017	9.8%	2.32 [1.88, 2.76]	-
Total (95% CI)	100.0%	2.84 [2.67, 3.01]	•
Heterogeneity: Tau ² = 0.03; Chi	² = 20.87, df =	16 (P = 0.18); P = 23%	
Test for overall effect: Z = 32.48	8 (P < 0.00001	Fav	ours [experimental] Favours [cor

medRxiv preprint doi: https://doi.org/10.1101/2024.05.16.24307477; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 7. Forrest plot of high/low miRNA expression

1.2MiRNA/PTENCorrelation

		Mean Difference	Mean Difference	
Study or Subgroup	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
Sun miR-181a-5p 2022	2.5%	-2.76 [-3.84, -1.68]	<	
Liu miRNA-29 2018	7.9%	-2.67 [-3.28, -2.06]	+	
Yuan miRNA-1908 2015	9.0%	-1.96 [-2.53, -1.39]		
Tian miR-128 2014	23.5%	-1.58 [-1.93, -1.23]		
Zhuang miRNA-524 2018	5.0%	-1.39 [-2.15, -0.63]		
Xiao miR-92a 2017	17.3%	-1.31 [-1.72, -0.90]		
Zhang miR-148a 2015	26.3%	-1.14 [-1.47, -0.81]		
Gao miR-17 2014	8.5%	-1.04 [-1.63, -0.45]		
Total (95% CI)	100.0%	-1.51 [-1.68, -1.34]	•	
Heterogeneity: Chi ² = 29.92, df = 7 (P < 0.0001); l ² = 77%				
Test for overall effect: Z = 17.34 (P < 0.00001)			Favours [experimental]	Favours [control]

medRxiv preprint doi: https://doi.org/10.1101/2024.05.16.24307477; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 8. Forrest plot of miRNA and PTEN expression cor



Figure 9. Funnel plot of high/low miRNA expression



Figure 1. PRISMA 2020 flow diagram.